Dose-adjusted EPOCH chemotherapy with bortezomib and raltegravir for human T-cell leukemia virus-associated adult T-cell leukemia lymphoma

Blood Cancer J. 2016 Mar 25;6(3):e408. doi: 10.1038/bcj.2016.21.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bortezomib / administration & dosage
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • HTLV-I Infections / complications*
  • HTLV-I Infections / virology
  • Human T-lymphotropic virus 1* / genetics
  • Humans
  • Leukemia-Lymphoma, Adult T-Cell / drug therapy*
  • Leukemia-Lymphoma, Adult T-Cell / etiology*
  • Leukemia-Lymphoma, Adult T-Cell / mortality
  • Prednisone / therapeutic use
  • Raltegravir Potassium / administration & dosage
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Raltegravir Potassium
  • Vincristine
  • Bortezomib
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • EPOCH protocol